{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:07:48Z","timestamp":1773184068587,"version":"3.50.1"},"reference-count":67,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T00:00:00Z","timestamp":1694217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Centre of Portuguese Oncology Institute of Porto","award":["CI-IPOP-74-2016"],"award-info":[{"award-number":["CI-IPOP-74-2016"]}]},{"name":"Research Centre of Portuguese Oncology Institute of Porto","award":["2022.11060.BD"],"award-info":[{"award-number":["2022.11060.BD"]}]},{"name":"Research Centre of Portuguese Oncology Institute of Porto","award":["SFRH\/BD\/136007\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136007\/2018"]}]},{"name":"Research Centre of Portuguese Oncology Institute of Porto","award":["SFRH\/BD\/143717\/2019"],"award-info":[{"award-number":["SFRH\/BD\/143717\/2019"]}]},{"name":"Portuguese League Against Cancer\u2014Northern Region","award":["CI-IPOP-74-2016"],"award-info":[{"award-number":["CI-IPOP-74-2016"]}]},{"name":"Portuguese League Against Cancer\u2014Northern Region","award":["2022.11060.BD"],"award-info":[{"award-number":["2022.11060.BD"]}]},{"name":"Portuguese League Against Cancer\u2014Northern Region","award":["SFRH\/BD\/136007\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136007\/2018"]}]},{"name":"Portuguese League Against Cancer\u2014Northern Region","award":["SFRH\/BD\/143717\/2019"],"award-info":[{"award-number":["SFRH\/BD\/143717\/2019"]}]},{"DOI":"10.13039\/501100001871","name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["CI-IPOP-74-2016"],"award-info":[{"award-number":["CI-IPOP-74-2016"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["2022.11060.BD"],"award-info":[{"award-number":["2022.11060.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/136007\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136007\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/143717\/2019"],"award-info":[{"award-number":["SFRH\/BD\/143717\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The three most common genitourinary malignancies (prostate\/kidney\/bladder cancers) constitute a substantial proportion of all cancer cases, mainly in the elderly population. Early detection is key to maximizing the patients\u2019 survival, but the lack of highly accurate biomarkers that might be used through non-\/minimally invasive methods has impaired progress in this domain. Herein, we sought to develop a minimally invasive test to detect and discriminate among those urological cancers based on miRNAs assessment through ddPCR. Plasma samples from 268 patients with renal cell (RCC; n = 119), bladder (BlCa; n = 73), and prostate (PCa; n = 76) carcinomas (UroCancer group), and 74 healthy donors were selected. Hsa-miR-126-3p, hsa-miR-141-3p, hsa-miR-153-5p, hsa-miR-155-5p, hsa-miR-182-5p, hsa-miR-205-5p, and hsa-miR-375-3p levels were assessed. UroCancer cases displayed significantly different circulating hsa-miR-182-5p\/hsa-miR-375-3p levels compared to healthy donors. Importantly, the hsa-miR-155-5p\/hsa-miR-375-3p panel detected RCC with a high specificity (80.54%) and accuracy (66.04%). Furthermore, the hsa-miR-126-3p\/hsa-miR-375-3p panel identified BlCa with a 94.87% specificity and 76.45% NPV whereas higher hsa-miR-126-3p levels were found in PCa patients. We concluded that plasma-derived miRNAs can identify and discriminate among the main genitourinary cancers, with high analytical performance. Although validation in a larger cohort is mandatory, these findings demonstrate that circulating miRNA assessment by ddPCR might provide a new approach for early detection and risk stratification of the most common urological cancers.<\/jats:p>","DOI":"10.3390\/ijms241813890","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:00:52Z","timestamp":1694422852000},"page":"13890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-3347","authenticated-orcid":false,"given":"Jos\u00e9 Pedro","family":"Sequeira","sequence":"first","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Doctoral Programme in Biomedical Sciences, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-6807","authenticated-orcid":false,"given":"Daniela","family":"Barros-Silva","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Patr\u00edcia","family":"Ferreira-Torre","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-1263","authenticated-orcid":false,"given":"Sofia","family":"Salta","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Doctoral Programme in Molecular Pathology and Genetics, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"given":"Isaac","family":"Braga","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Urology & Urology Clinics, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Doctoral Programme in Medical Sciences, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"given":"Jo\u00e3o","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Urology & Urology Clinics, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Doctoral Programme in Medical Sciences, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"given":"Rui","family":"Freitas","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Urology & Urology Clinics, Portuguese Oncology Institute of Porto (IPOP), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Doctoral Programme in Medical Sciences, ICBAS-School of Medicine & Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2013School of Medicine and Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2013School of Medicine and Biomedical Sciences, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhai, X., Yi, P., Wang, X., Wang, H., Yang, X., Mei, Z., and Ge, M. (2022). Effect of statins on risk and mortality of urologic malignancies: Protocol of an umbrella review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264076"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.22465\/juo.234600080004","article-title":"Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades","volume":"21","author":"Han","year":"2023","journal-title":"J. Urol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global Burden of Urologic Cancers, 1990\u20132013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cancers15010100","article-title":"Current Status of Research on Small Extracellular Vesicles for the Diagnosis and Treatment of Urological Tumors","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (2020). United States Cancer Statistics: Male Urologic Cancers, USCS Data Brief."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Manini, C., and L\u00f3pez, J.I. (2021). Insights into Urological Cancer. Cancers, 13.","DOI":"10.3390\/cancers13020204"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9864047","DOI":"10.1155\/2016\/9864047","article-title":"New Progress of Epigenetic Biomarkers in Urological Cancer","volume":"2016","author":"Wu","year":"2016","journal-title":"Dis. Markers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41585-020-0363-3","article-title":"Current evidence on screening for renal cancer","volume":"17","author":"Simmons","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1590\/S1677-55382009000500003","article-title":"Prostatic specific antigen for prostate cancer detection","volume":"35","author":"Nogueira","year":"2009","journal-title":"Int. Braz. J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: Update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1590\/S1677-5538.IBJU.2013.05.04","article-title":"Comparison of urinary and serum CA 19-9 as markers of early stage urothelial carcinoma","volume":"39","author":"Roy","year":"2013","journal-title":"Int. Braz. J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cardinali, B., Tasso, R., Piccioli, P., Ciferri, M.C., Quarto, R., and Del Mastro, L. (2022). Circulating miRNAs in Breast Cancer Diagnosis and Prognosis. Cancers, 14.","DOI":"10.3390\/cancers14092317"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fgene.2019.00626","article-title":"Circulating microRNAs in cancer: Potential and challenge","volume":"10","author":"Cui","year":"2019","journal-title":"Front. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sequeira, J.P., Const\u00e2ncio, V., Lobo, J., Henrique, R., and Jer\u00f3nimo, C. (2021). Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13215252"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-018-0492-1","article-title":"Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage","volume":"10","author":"Wang","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Aveta, A., Cilio, S., Contieri, R., Spena, G., Napolitano, L., Manfredi, C., Franco, A., Crocerossa, F., Cerrato, C., and Ferro, M. (2023). Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1974.v1"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Adam-Artigues, A., Garrido-Cano, I., Carbonell-Asins, J.A., Lameirinhas, A., Sim\u00f3n, S., Ortega-Morillo, B., Mart\u00ednez, M.T., Hernando, C., Const\u00e2ncio, V., and Burgues, O. (2021). Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13112848"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3389\/fgene.2019.00815","article-title":"Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer","volume":"10","author":"Amorim","year":"2019","journal-title":"Front. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41419-017-0241-y","article-title":"MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis","volume":"9","author":"Duarte","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13148-015-0076-2","article-title":"MicroRNA-375 plays a dual role in prostate carcinogenesis","volume":"7","author":"Vieira","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12967-019-02193-y","article-title":"Overexpression of circulating MiR-30b-5p identifies advanced breast cancer","volume":"17","author":"Lobo","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lobo, J., Gillis, A.J.M., van den Berg, A., Dorssers, L.C.J., Belge, G., Dieckmann, K.P., Roest, H.P., van der Laan, L.J.W., Gietema, J., and Hamilton, R.J. (2019). Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells, 8.","DOI":"10.3390\/cells8121637"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sequeira, J.P., Const\u00e2ncio, V., Salta, S., Lobo, J., Barros-Silva, D., Carvalho-Maia, C., Rodrigues, J., Braga, I., Henrique, R., and Jer\u00f3nimo, C. (2022). LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14040858"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"876732","DOI":"10.3389\/fonc.2022.876732","article-title":"DigiMir test: Establishing a novel pipeline for MiR-371a quantification using droplet digital PCR in liquid biopsies from testicular germ cell tumor patients","volume":"12","author":"Sequeira","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1093\/nar\/gkq601","article-title":"Export of microRNAs and microRNA-protective protein by mammalian cells","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fonc.2019.00900","article-title":"Circulating microRNAs as biomarkers for prostate cancer detection and metastasis development prediction","volume":"9","author":"Bidarra","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urology.2017.03.013","article-title":"Serum microRNA Expression Profiling: Potential Diagnostic Implications of a Panel of Serum microRNAs for Clear Cell Renal Cell Cancer","volume":"104","author":"Yadav","year":"2017","journal-title":"Urology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41598-019-57101-7","article-title":"Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer","volume":"10","author":"Zedan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/ijo.2013.2169","article-title":"Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma","volume":"44","author":"Iwamoto","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wulfken, L.M., Moritz, R., Ohlmann, C., Holdenrieder, S., Jung, V., Becker, F., Herrmann, E., Walgenbach-Br\u00fcnagel, G., von Ruecker, A., and M\u00fcller, S.C. (2011). MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025787"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1038\/s41598-020-61507-z","article-title":"Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: A systematic and paired comparative analysis","volume":"10","author":"Costa","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/CIRCRESAHA.111.300539","article-title":"Circulating microRNAs as novel biomarkers for platelet activation","volume":"112","author":"Willeit","year":"2013","journal-title":"Circ. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/cr.2007.67","article-title":"Beginning to understand microRNA function","volume":"17","author":"Du","year":"2007","journal-title":"Cell Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Oeyen, E., Hoekx, L., De Wachter, S., Baldewijns, M., Ameye, F., and Mertens, I. (2019). Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040821"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mathai, R.A., Vidya, R.V.S., Reddy, B.S., Thomas, L., Udupa, K., Kolesar, J., and Rao, M. (2019). Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030373"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41585-020-0297-9","article-title":"Harnessing cell-free DNA: Plasma circulating tumour DNA for liquid biopsy in genitourinary cancers","volume":"17","author":"Maia","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14737159.2019.1633307","article-title":"The potential of circulating cell free RNA as a biomarker in cancer","volume":"19","author":"Cheung","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14737159.2019.1604224","article-title":"Known epigenetic biomarkers for prostate cancer detection and management: Exploring the potential of blood-based liquid biopsies","volume":"19","author":"Henrique","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ali Syeda, Z., Langden, S.S.S., Munkhzul, C., Lee, M., and Song, S.J. (2020). Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051723"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Campomenosi, P., Gini, E., Noonan, D.M., Poli, A., D\u2019Antona, P., Rotolo, N., Dominioni, L., and Imperatori, A. (2016). A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. BMC Biotechnol., 16.","DOI":"10.1186\/s12896-016-0292-7"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/s41598-017-02217-x","article-title":"Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: From variable nonsense to publication quality data","volume":"7","author":"Taylor","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mancini, M., Righetto, M., Zumerle, S., Montopoli, M., and Zattoni, F. (2020). The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186542"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e3118","DOI":"10.1016\/S1569-9056(19)33362-7","article-title":"P52\u2014Genomic subtypes of bladder cancer with distinct methylation profiles could be better identified by the Bladder EpiCheck test as compared to cystoscopy\/urine cytology","volume":"18","author":"Righetto","year":"2019","journal-title":"Eur. Urol. Suppl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncy.22152","article-title":"Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer","volume":"127","author":"Trenti","year":"2019","journal-title":"Cancer Cytopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22246","article-title":"Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer","volume":"128","author":"Trenti","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.juro.2016.02.2496","article-title":"MP13-15 molecular urine cytology\u2014bladder epicheck is a novel molecular diagnostic tool for monitoring of bladder cancer patients","volume":"195","author":"Wasserstrom","year":"2016","journal-title":"J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Merriel, S.W.D., Pocock, L., Gilbert, E., Creavin, S., Walter, F.M., Spencer, A., and Hamilton, W. (2022). Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med., 20.","DOI":"10.1186\/s12916-021-02230-y"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kirschner, M.B., Kao, S.C., Edelman, J.J., Armstrong, N.J., Vallely, M.P., van Zandwijk, N., and Reid, G. (2011). Hemolysis during Sample Preparation Alters microRNA Content of Plasma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024145"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","article-title":"Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies","volume":"5","author":"Pritchard","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Smith, M.D., Leemaqz, S.Y., Jankovic-Karasoulos, T., McAninch, D., McCullough, D., Breen, J., Roberts, C.T., and Pillman, K.A. (2022). Hemolysis Detection in MicroRNA-Seq from Clinical Plasma Samples. Genes, 13.","DOI":"10.1101\/2022.03.27.22273016"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4236\/aar.2014.32023","article-title":"Effect of aging and sex on circulating microRNAs in humans","volume":"3","author":"Sawada","year":"2014","journal-title":"Adv. Aging Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.18632\/aging.101613","article-title":"Age- and sex-dependent changes in levels of circulating brain-enriched microRNAs during normal aging","volume":"10","author":"Sheinerman","year":"2018","journal-title":"Aging"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ameling, S., Kacprowski, T., Chilukoti, R.K., Malsch, C., Liebscher, V., Suhre, K., Pietzner, M., Friedrich, N., Homuth, G., and Hammer, E. (2015). Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study. BMC Med. Genomics, 8.","DOI":"10.1186\/s12920-015-0136-7"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gonella-Diaza, A.M., Lopes, E., Ribeiro da Silva, K., Perecin Nociti, R., Mamede Andrade, G., Atuesta-Bustos, J.E., Coelho da Silveira, J., Vieira Meirelles, F., and Binelli, M. (2021). Steroidal Regulation of Oviductal microRNAs Is Associated with microRNA-Processing in Beef Cows. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020953"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17650","DOI":"10.1038\/s41598-018-35974-4","article-title":"Circulating small non-coding RNAs associated with age, sex, smoking, body mass and physical activity","volume":"8","author":"Rounge","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.3390\/molecules19056080","article-title":"Issues and prospects of microRNA-based biomarkers in blood and other body fluids","volume":"19","author":"Chevillet","year":"2014","journal-title":"Molecules"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Glinge, C., Clauss, S., Boddum, K., Jabbari, R., Jabbari, J., Risgaard, B., Tomsits, P., Hildebrand, B., K\u00e4\u00e4b, S., and Wakili, R. (2017). Stability of Circulating Blood-Based MicroRNAs\u2014Pre-Analytic Methodological Considerations. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0167969"},{"key":"ref_60","unstructured":"Yu, B., and Chen, X. (2010). Plant MicroRNAs: Methods and Protocols, Humana Press."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sarver, A.L., Sarver, A.E., Yuan, C., and Subramanian, S. (2018). OMCD: OncomiR Cancer Database. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5085-z"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","article-title":"Determining lower limits of detection of digital PCR assays for cancer-related gene mutations","volume":"1","author":"Milbury","year":"2014","journal-title":"Biomol. Detect. Quantif."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"16389","DOI":"10.1038\/s41598-018-34597-z","article-title":"Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer","volume":"8","author":"Tavano","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ruiz-Plazas, X., Altuna-Coy, A., Alves-Santiago, M., Vila-Barja, J., Garc\u00eda-Fontgivell, J.F., Mart\u00ednez-Gonz\u00e1lez, S., Segarra-Tom\u00e1s, J., and Chac\u00f3n, M.R. (2021). Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness. Cancers, 13.","DOI":"10.3390\/cancers13020250"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.ede.0000147512.81966.ba","article-title":"Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples","volume":"16","author":"Schisterman","year":"2005","journal-title":"Epidemiology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/13890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:47:57Z","timestamp":1760129277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/18\/13890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,9]]},"references-count":67,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ijms241813890"],"URL":"https:\/\/doi.org\/10.3390\/ijms241813890","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,9]]}}}